212 related articles for article (PubMed ID: 22079685)
1. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization.
Fefer P; Tsimikas S; Segev A; Sparkes J; Otsuka F; Kolodgie F; Virmani R; Juliano J; Charron T; Strauss BH
Cardiovasc Revasc Med; 2012; 13(1):11-9. PubMed ID: 22079685
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
[TBL] [Abstract][Full Text] [Related]
3. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
[TBL] [Abstract][Full Text] [Related]
4. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
[TBL] [Abstract][Full Text] [Related]
5. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
6. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
7. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
[TBL] [Abstract][Full Text] [Related]
8. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium.
Ahmadi N; Tsimikas S; Hajsadeghi F; Saeed A; Nabavi V; Bevinal MA; Kadakia J; Flores F; Ebrahimi R; Budoff MJ
Am J Cardiol; 2010 Feb; 105(4):459-66. PubMed ID: 20152239
[TBL] [Abstract][Full Text] [Related]
9. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
10. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
[TBL] [Abstract][Full Text] [Related]
11. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.
Arai K; Luke MM; Koschinsky ML; Miller ER; Pullinger CR; Witztum JL; Kane JP; Tsimikas S
Atherosclerosis; 2010 Apr; 209(2):498-503. PubMed ID: 19880117
[TBL] [Abstract][Full Text] [Related]
12. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.
Taleb A; Witztum JL; Tsimikas S
Biomark Med; 2011 Oct; 5(5):673-94. PubMed ID: 22003918
[TBL] [Abstract][Full Text] [Related]
13. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
[TBL] [Abstract][Full Text] [Related]
14. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).
Yeang C; Hung MY; Byun YS; Clopton P; Yang X; Witztum JL; Tsimikas S
J Clin Lipidol; 2016; 10(3):594-603. PubMed ID: 27206947
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
16. Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina.
Leibundgut G; Lee JH; Strauss BH; Segev A; Tsimikas S
J Thromb Thrombolysis; 2016 May; 41(4):569-80. PubMed ID: 26964999
[TBL] [Abstract][Full Text] [Related]
17. Association of D-dimer with Plaque Characteristics and Plasma Biomarkers of Oxidation-Specific Epitopes in Stable Subjects with Coronary Artery Disease.
Kothari H; Nguyen AT; Yang X; Hisada Y; Tsimikas S; Mackman N; Taylor A; McNamara CA
J Cardiovasc Transl Res; 2018 Jun; 11(3):221-229. PubMed ID: 29344841
[TBL] [Abstract][Full Text] [Related]
18. Oxidation-specific biomarkers and risk of peripheral artery disease.
Bertoia ML; Pai JK; Lee JH; Taleb A; Joosten MM; Mittleman MA; Yang X; Witztum JL; Rimm EB; Tsimikas S; Mukamal KJ
J Am Coll Cardiol; 2013 May; 61(21):2169-79. PubMed ID: 23541965
[TBL] [Abstract][Full Text] [Related]
19. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
[TBL] [Abstract][Full Text] [Related]
20. Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a).
Krychtiuk KA; Kastl SP; Hofbauer SL; Wonnerth A; Goliasch G; Ozsvar-Kozma M; Katsaros KM; Maurer G; Huber K; Dostal E; Binder CJ; Pfaffenberger S; Oravec S; Wojta J; Speidl WS
J Clin Lipidol; 2015; 9(4):533-41. PubMed ID: 26228671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
